Kinetic constants and sample-to-sample variation in the rate of metabolism of two or more substrates for human liver microsomal CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP3A4

被引：0
|
作者：
Woodworth, Zell [1 ]
Dwyer, L. Anne [1 ]
Collins, Lisa [1 ]
Graves, Terry [1 ]
Helmstetter, Stephanie [1 ]
Ogilvie, Brian [1 ]
Otwell, Clayton [1 ]
Pope, Chad [1 ]
Ramsey, Tiffin [1 ]
Yerino, Phyllis [1 ]
Parkinson, Andrew [1 ]
机构：
[1] XenoTech LLC, Lenexa, KS USA
来源：
DRUG METABOLISM REVIEWS | 2006年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
107
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [41] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Lauri I. Kajosaari
    Tiina Jaakkola
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2006, 62 : 217 - 223
  • [42] The involvement of CYP3A4 and CYP2C9 in the metabolism of 17α-ethinylestradiol
    Wang, B
    Sanchez, RI
    Franklin, RB
    Evans, DC
    Huskey, SEW
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (11) : 1209 - 1212
  • [43] Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
    Kudzi, William
    Dodoo, Alexander N. O.
    Mills, Jeremy J.
    BMC MEDICAL GENETICS, 2009, 10
  • [44] Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6
    Lu, H.
    Wang, J. J.
    Chan, K. K.
    Philip, P. A.
    XENOBIOTICA, 2006, 36 (05) : 367 - 385
  • [45] Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
    Yasar, U
    Lundgren, S
    Eliasson, E
    Bennet, A
    Wiman, B
    de Faire, U
    Rane, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (01) : 25 - 28
  • [46] Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
    Wang, JS
    DeVane, CL
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (06) : 742 - 747
  • [47] CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 257 - 267
  • [48] Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
    Tan, Ming-Liang
    Yoshida, Kenta
    Zhao, Ping
    Zhang, Lei
    Nolin, Thomas D.
    Piquette-Miller, Micheline
    Galetin, Aleksandra
    Huang, Shiew-Mei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 854 - 867
  • [49] Pharmacogenetics of acenocoumarol:: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) : 641 - 649
  • [50] Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts
    Pan, Yan
    Tiong, Kai Hung
    Abd-Rashid, Badrul Amini
    Ismail, Zakiah
    Ismail, Rushli
    Mak, Joon Wah
    Ong, Chin Eng
    JOURNAL OF ETHNOPHARMACOLOGY, 2012, 143 (02) : 586 - 591
12345